ES2074037T3 - Uso del dimero de lisozima para la fabricacion de un medicamento para modular los mecanismos de defensa naturales. - Google Patents

Uso del dimero de lisozima para la fabricacion de un medicamento para modular los mecanismos de defensa naturales.

Info

Publication number
ES2074037T3
ES2074037T3 ES93915903T ES93915903T ES2074037T3 ES 2074037 T3 ES2074037 T3 ES 2074037T3 ES 93915903 T ES93915903 T ES 93915903T ES 93915903 T ES93915903 T ES 93915903T ES 2074037 T3 ES2074037 T3 ES 2074037T3
Authority
ES
Spain
Prior art keywords
lysozyme
tnf
use according
dimerized
dimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93915903T
Other languages
English (en)
Spanish (es)
Other versions
ES2074037T1 (es
Inventor
Witold Kiczka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nika Health Products Ltd
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of ES2074037T1 publication Critical patent/ES2074037T1/es
Application granted granted Critical
Publication of ES2074037T3 publication Critical patent/ES2074037T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES93915903T 1992-07-13 1993-07-13 Uso del dimero de lisozima para la fabricacion de un medicamento para modular los mecanismos de defensa naturales. Expired - Lifetime ES2074037T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL29527392 1992-07-13
PL92295273A PL173978B1 (pl) 1992-07-13 1992-07-13 Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej

Publications (2)

Publication Number Publication Date
ES2074037T1 ES2074037T1 (es) 1995-09-01
ES2074037T3 true ES2074037T3 (es) 2004-07-01

Family

ID=20058087

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93915903T Expired - Lifetime ES2074037T3 (es) 1992-07-13 1993-07-13 Uso del dimero de lisozima para la fabricacion de un medicamento para modular los mecanismos de defensa naturales.

Country Status (31)

Country Link
US (1) US6132715A (https=)
EP (1) EP0651654B1 (https=)
JP (1) JPH07508744A (https=)
KR (1) KR100289841B1 (https=)
CN (1) CN1057937C (https=)
AT (1) ATE252392T1 (https=)
AU (1) AU677786B2 (https=)
BG (1) BG63331B1 (https=)
BR (1) BR9306722A (https=)
CA (1) CA2140140A1 (https=)
CZ (1) CZ286725B6 (https=)
DE (2) DE69333258T2 (https=)
DK (1) DK0651654T3 (https=)
ES (1) ES2074037T3 (https=)
FI (1) FI950144A0 (https=)
GE (1) GEP20012466B (https=)
GR (1) GR950300039T1 (https=)
HU (1) HU218151B (https=)
MX (1) MX9304197A (https=)
NZ (2) NZ254135A (https=)
OA (1) OA10125A (https=)
PL (1) PL173978B1 (https=)
PT (1) PT651654E (https=)
RO (1) RO112580B1 (https=)
RU (1) RU2145875C1 (https=)
SG (1) SG52727A1 (https=)
SK (1) SK282377B6 (https=)
TW (1) TW259710B (https=)
UA (1) UA49789C2 (https=)
WO (1) WO1994001127A1 (https=)
ZA (1) ZA935046B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
DZ1964A1 (fr) * 1995-01-13 2002-10-15 Nika Health Products Ltd Nouvelle applications d'un dimère de lysozyme.
AU5884096A (en) * 1995-05-30 1996-12-18 Lectin Biopharma, Inc. Method of using lectins for agglutination and collection of menstrual flow
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
EP1174147A1 (en) * 2000-06-27 2002-01-23 Nika Health Products Limited Reversal of antibiotic resistance with lysozyme dimer
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
RU2320367C1 (ru) * 2006-08-22 2008-03-27 Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) Способ сопроводительного лечения острого лимфобластного лейкоза
RU2351351C1 (ru) * 2007-08-08 2009-04-10 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, повышающее неспецифическую сопротивляемость организма к бактериальным эндотоксинам
RU2472467C2 (ru) * 2011-04-13 2013-01-20 Государственное научное учреждение Краснодарский научно-исследовательский ветеринарный институт (ГНУ КНИВИ) Способ профилактики и лечения гастроэнтеритов, обусловленных бактериозами, у телят
CN105106626A (zh) * 2015-09-30 2015-12-02 成都倍加特生物科技有限公司 一种治疗月经期感染的汤剂药物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4020M (https=) * 1965-01-29 1966-03-21
FR2215201A1 (en) * 1973-01-24 1974-08-23 Theranol Lab Broad-spectrum antibiotic compsns. - contg. antibiotic resistant lactic bacilli and enzyme diffusing-agent
JPS5533408A (en) * 1978-08-30 1980-03-08 Eisai Co Ltd Immunity-increasing agent
JPS5533409A (en) * 1978-08-30 1980-03-08 Eisai Co Ltd Carcinostatic agent
JPS5543040A (en) * 1978-09-25 1980-03-26 Eisai Co Ltd Immunity raising agent
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4457919A (en) * 1980-03-14 1984-07-03 Newport Pharmaceutical International, Inc. Method of imparting immunomodulating, antiviral or antitumor activity
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
EP0238851B1 (en) * 1986-02-19 1992-12-09 Imreg, Inc. A method and means of assaying an immune system
EP0380484B1 (en) * 1988-05-26 1993-08-18 Nika Health Products Limited Use of a lysozyme dimer and/or a ribonuclease dimer for th emanufacture of an antiviral or antibiotic drug
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
AU3765689A (en) * 1988-05-31 1990-01-05 Napp Systems (U.S.A.) Inc. Apparatus and process for processing printing plates
KR920702621A (ko) * 1989-06-13 1992-10-06 스튜어트 알. 슈터 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
HU214509B (hu) * 1990-01-08 1998-03-30 Nika Health Products Ltd. Eljárás tisztított lizozim dimerek előállítására
US5314816A (en) * 1990-01-08 1994-05-24 Nika Health Products Ltd. Method of preparing lysozyme dimers
WO1992002220A1 (en) * 1990-08-03 1992-02-20 Smithkline Beecham Corporation Tnf inhibitors

Also Published As

Publication number Publication date
SG52727A1 (en) 1998-09-28
CZ8595A3 (en) 1995-09-13
DE69333258T2 (de) 2004-08-26
JPH07508744A (ja) 1995-09-28
EP0651654B1 (en) 2003-10-22
AU677786B2 (en) 1997-05-08
HUT70973A (en) 1995-11-28
CN1087278A (zh) 1994-06-01
TW259710B (https=) 1995-10-11
MX9304197A (es) 1994-02-28
WO1994001127A1 (en) 1994-01-20
FI950144L (fi) 1995-01-12
HU218151B (hu) 2000-06-28
HU9500098D0 (en) 1995-03-28
ATE252392T1 (de) 2003-11-15
ES2074037T1 (es) 1995-09-01
SK282377B6 (sk) 2002-01-07
BG63331B1 (bg) 2001-10-31
PL173978B1 (pl) 1998-05-29
US6132715A (en) 2000-10-17
CZ286725B6 (en) 2000-06-14
DE69333258D1 (de) 2003-11-27
ZA935046B (en) 1994-02-07
DE651654T1 (de) 1996-01-04
KR100289841B1 (ko) 2001-05-15
OA10125A (en) 1996-12-18
RU2145875C1 (ru) 2000-02-27
UA49789C2 (uk) 2002-10-15
KR950702432A (ko) 1995-07-29
PT651654E (pt) 2004-03-31
BG99287A (bg) 1995-08-28
FI950144A7 (fi) 1995-01-12
NZ254135A (en) 1996-11-26
GR950300039T1 (en) 1995-07-31
DK0651654T3 (da) 2004-02-23
EP0651654A1 (en) 1995-05-10
RO112580B1 (ro) 1997-11-28
CN1057937C (zh) 2000-11-01
NZ299377A (en) 2001-02-23
FI950144A0 (fi) 1995-01-12
SK4095A3 (en) 1995-09-13
GEP20012466B (en) 2001-06-25
AU4568693A (en) 1994-01-31
BR9306722A (pt) 1998-12-08
CA2140140A1 (en) 1994-01-20
PL295273A1 (en) 1994-01-24

Similar Documents

Publication Publication Date Title
Gruet et al. Bovine mastitis and intramammary drug delivery: review and perspectives
CA1335425C (en) Antiviral or antibacterial compound and method of use
ES2074037T3 (es) Uso del dimero de lisozima para la fabricacion de un medicamento para modular los mecanismos de defensa naturales.
ES2994966T3 (en) Single doses of oritavancin for treating or preventing a bacterial infection
RU2667974C2 (ru) Фармацевтическая комбинированная композиция для местного и наружного применения на основе диоксидина
CN102283842A (zh) 一种复方乙酰甲喹氟苯尼考纳米乳抗菌药物及其制备方法
RU2367433C1 (ru) Препарат для лечения мастита у коров в период лактации
HUT63335A (en) Process for producing pharmaceutical compositions for treating diseases of mammals
JPH06340549A (ja) ネコの呼吸器疾患治療剤とその治療剤を用いる治療方法
RU2262350C2 (ru) Вакцина для иммунопрофилактики и иммунотерапии заболеваний человека и животных, вызванных патогенными и условно-патогенными грамотрицательными микроорганизмами кишечной группы и их экзотоксинами, и способ ее получения (варианты), иммуноглобулиновый препарат (варианты) и способ его получения, иммунобиологический препарат, поликомпонентная вакцина
Brown et al. Muramyl dipeptide enhances survival from experimental peritonitis
JP4629964B2 (ja) ウシの消化器疾患治療剤
CA1285226C (en) Compositions containing a 2,4-diamino-pyrimidine and sulphadimidine
RU2652276C1 (ru) Способ лечения послеродового эндометрита у коров
PL176407B1 (pl) Kompozycja farmaceutyczna zawierająca dimer lizozymu
CN101912405A (zh) 一种治疗牛子宫内膜炎的药物组合物
RU2681523C2 (ru) Состав для лечения диарейного синдрома при кишечных инфекциях телят в молочный период выращивания
ITMI20091122A1 (it) Formulazioni farmaceutiche per uso intravaginale nella prevenzione e terapia delle vulvo vaginiti e nel ripristino della fisiologia vaginale
Aswad et al. Formulation and Evaluation of Snakehead Fish Mucus Emulgel for Enhanced Wound Healing and Antibacterial Activity
KR20240128192A (ko) 항염증 펩타이드 pn5를 포함하는 염증성 질환의 예방 또는 치료용 조성물
JPWO2007037099A1 (ja) 乳房炎の治療剤